Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.42 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9671488 | 0.86 | FDPS (0.49) | FDPSALDH1A1TSHRAOX1MAPT | |
| SCHEMBL31160627 | 0.86 | FDPS (0.64) | FDPSALDH1A1TSHRAOX1MAPT | |
| SCHEMBL4255761 | 0.86 | FDPS (0.64) | FDPSALDH1A1TSHRAOX1MAPT | |
| SCHEMBL5455295 | 0.85 | FDPS (0.63) | FDPSALDH1A1TSHRAOX1MAPT | |
| SCHEMBL7643558 | 0.83 | TRPA1 (0.42) | FDPSALDH1A1TSHRMAPTHPGD | |
| SCHEMBL31054299 | 0.83 | FDPS (0.75) | FDPSALDH1A1TSHRAOX1MAPT | |
| SCHEMBL3394561 | 0.83 | ALDH1A1 (0.70) | FDPSALDH1A1TSHRAOX1MAPT | |
| SCHEMBL2850023 | 0.83 | FDPS (0.75) | FDPSALDH1A1TSHRAOX1MAPT | |
| SCHEMBL3721435 | 0.82 | ALDH1A1 (0.62) | FDPSALDH1A1TSHRAOX1MAPT | |
| SCHEMBL9454852 | 0.81 | ALDH1A1 (0.67) | FDPSALDH1A1TSHRAOX1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012390-B2 | Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-112601743-B | Flavone compounds for the treatment and prevention of hepatitis b virus diseases | 豪夫迈·罗氏有限公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-3849966-B1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20220363657-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-3849966-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| CN-112601743-A | Flavone compounds for treating and preventing hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2021-04-02 | — | — | CN | disclosed |
| WO-2020053249-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020052774-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020052774-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| EP-1506195-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | EP | disclosed |
| CN-1318421-C | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2007-05-30 | — | — | CN | disclosed |
| CN-1653066-A | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2005-08-10 | — | — | CN | disclosed |
| EP-1506195-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2005-02-16 | — | — | EP | disclosed |
| US-6806265-B2 | FOR THERAPY AND PROPHYLAXIS OF HIV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-19 | — | — | US | disclosed |
| US-20040006071-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2004-01-08 | — | — | US | disclosed |
| WO-2003097644-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012390-B2 | Flavone compounds for the treatment and prophylaxis of hepatitis B virus disease | PCNA, DNMT1, DNMT3B | FDPS 232/4885ALDH1A1 1894/4885TSHR 4171/4885 |
| US-20040006071-A1 | Non-nucleoside reverse transcriptase inhibitors | CBR1, POLR2H, SUB1 | FDPS 2750/4885ALDH1A1 922/4885TSHR 797/4885 |
| US-20220363657-A1 | FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | PCNA, DNMT1, DNMT3B | FDPS 232/4885ALDH1A1 1894/4885TSHR 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.